SOLVE-TAVI: One-year outcomes of a factorial randomized trial of self-expandable vs balloon-expandable TAVR and general vs local anesthesia

Reported from the TCT Congress 2020

Reporting from TCT Connect 2020, Mirvat Alasnag interviews Hans-Josef Feistritzer who presented the results of the SOLVE-TAVI trial.

In this short interview, Mirvat Alasnag interviews Hans-Josef Feistritzer (Leipzig, Germany). After describing the unique study design, Prof. Feistritzer answers the following questions:

What were the pre-specified subgroups for the analysis?
What are the most important results of this trial?
How can we explain the low rates of stroke with the self-expanding valves?
What is the explanation for the high rates of permanent pacemakers in this trial?
Can the results of the study be extended to lower risk populations (regarding the STS score)?
How does this trial differ from other similar trials?
Is there any particular difference between female and male subgroups?